{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-022864","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.250229+00:00","generated_at":"2026-05-22T08:22:09.451882+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"C4 Therapeutics Q1 net loss $26.3M; cemsidomide 50% ORR at 100 µg in MM","bullets":["Revenue $7.2M (up from $3.0M YoY); net loss $0.37/share vs $0.41.","Cemsidomide Phase 1 MM dose escalation complete; 100 µg QD safe for expansion; ORR 50% at 100 µg, 40% at 75 µg.","One patient achieved MRD-negative complete response after prior T-cell engager therapies.","Will not advance CFT1946 beyond Phase 1; seeking partnership for BRAF program.","Cash $234.7M, runway into 2027; earned $4M from two Roche preclinical milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-022864","json":"https://secwatch.observer/filing/0001628280-25-022864.json","markdown":"https://secwatch.observer/filing/0001628280-25-022864.md","text":"https://secwatch.observer/filing/0001628280-25-022864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828025022864/0001628280-25-022864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828025022864/cccc-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T08:22:09.451882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}